Natixis Advisors LLC Has $4.85 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

Natixis Advisors LLC decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 19.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,735 shares of the biotechnology company's stock after selling 3,276 shares during the quarter. Natixis Advisors LLC's holdings in United Therapeutics were worth $4,847,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of UTHR. Great Lakes Advisors LLC lifted its position in United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock worth $697,000 after buying an additional 31 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock worth $3,214,000 after purchasing an additional 33 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of United Therapeutics by 0.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company's stock valued at $1,761,000 after purchasing an additional 39 shares during the last quarter. MBM Wealth Consultants LLC increased its holdings in shares of United Therapeutics by 1.9% in the fourth quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company's stock valued at $775,000 after purchasing an additional 41 shares in the last quarter. Finally, UMB Bank n.a. raised its position in United Therapeutics by 4.9% in the 4th quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company's stock worth $388,000 after purchasing an additional 51 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. UBS Group boosted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $388.25.

United Therapeutics Stock Down 1.5 %

United Therapeutics stock traded down $4.77 during midday trading on Tuesday, hitting $315.09. 39,520 shares of the stock were exchanged, compared to its average volume of 446,533. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82. The stock has a market capitalization of $14.15 billion, a PE ratio of 13.84, a P/E/G ratio of 0.97 and a beta of 0.64. The company has a fifty day simple moving average of $344.24 and a two-hundred day simple moving average of $356.84.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same quarter in the previous year, the business earned $4.36 EPS. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $956,195.85. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Nilda Mesa sold 255 shares of the company's stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now directly owns 5,528 shares of the company's stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 80,255 shares of company stock valued at $28,995,021. Company insiders own 11.90% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.